Maham Fatima
2 min read
In This Article:
Argenx (NASDAQ:ARGX) is one of the best biotech stocks to invest in now. On June 20, Argenx announced that the European Commission/EC approved VYVGART (efgartigimod alfa) 1000mg for subcutaneous/SC injection. The approval is for its use as a monotherapy in adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy/CIDP who have previously been treated with corticosteroids or immunoglobulins.
VYVGART SC is available as a vial or prefilled syringe and offers a flexible administration option, which allows it to be given by a patient, caregiver, or healthcare professional. Treatment begins with a weekly dose regimen, which can be adjusted to every other week based on clinical evaluation. This marks the first approval of an IgG Fc-antibody fragment specifically targeting the neonatal Fc receptor (FcRn) for CIDP in Europe, and it represents the first novel mechanism of action for CIDP treatment in 30+ years.
A lab setting filled with scientific equipment and researchers in lab coats working together to develop new therapies for autoimmune diseases.
The EC’s decision follows a positive recommendation from the Committee for Medicinal Products for Human Use/CHMP and is supported by the results of the ADHERE clinical trial, which is the largest study conducted to date on CIDP patients. CIDP is a rare, debilitating, and often progressive immune-mediated neuromuscular disorder affecting the peripheral nervous system. The EC approval covers all 27 European Union Member States, as well as Iceland, Liechtenstein, and Norway.
Argenx (NASDAQ:ARGX) is a commercial-stage biopharma company that develops various therapies for the treatment of autoimmune diseases in the US, Japan, China, the Netherlands, and internationally.
While we acknowledge the potential of ARGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
